Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics

 
• By Bridget Silverman
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers